Arsanis Inc. (NASDAQ:ASNS) and Coherus BioSciences Inc. (NASDAQ:CHRS), both competing one another are Biotechnology companies. We will compare their dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation.
Valuation and Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Coherus BioSciences Inc.||N/A||0.00||195.81M||-3.13||0.00|
In table 1 we can see Arsanis Inc. and Coherus BioSciences Inc.’s top-line revenue, earnings per share and valuation.
Table 2 shows us the net margins, return on equity and return on assets of both companies.
|Net Margins||Return on Equity||Return on Assets|
|Coherus BioSciences Inc.||0.00%||-741.7%||-126.2%|
The Current Ratio and a Quick Ratio of Arsanis Inc. are 5.1 and 5.1. Competitively, Coherus BioSciences Inc. has 5.3 and 5.3 for Current and Quick Ratio. Coherus BioSciences Inc.’s better ability to pay short and long-term obligations than Arsanis Inc..
In next table is pshown Arsanis Inc. and Coherus BioSciences Inc.’s ratings and recommmendations.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Coherus BioSciences Inc.||0||0||1||3.00|
Competitively Coherus BioSciences Inc. has a average target price of $28, with potential upside of 139.32%.
Insider and Institutional Ownership
Arsanis Inc. and Coherus BioSciences Inc. has shares owned by institutional investors as follows: 75.5% and 95.7%. Arsanis Inc.’s share owned by insiders are 1.8%. Competitively, Coherus BioSciences Inc. has 0.1% of it’s share owned by insiders.
Arsanis, Inc., a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address serious infectious diseases. Its lead product candidate is ASN100, a first-in-class mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia. The company’s preclinical pipeline comprises mAbs targeting multiple serious bacterial and viral pathogens, including respiratory syncytial virus. Arsanis, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
Coherus BioSciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The companyÂ’s product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, nonÂ–small cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma. Its product candidates also comprise CHS-1420, an adalimumab biosimilar candidate, which is in various phases of clinical trials to treat ankylosing spondylitis, BehÃ§et’s Disease, CrohnÂ’s Disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis; and CHS-3351, a ranibizumab biosimilar candidate, which is in preclinical stage for the treatment of neovascular (wet) age-related macular, degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. Coherus Biosciences, Inc. has license agreement with Daiichi Sankyo Company, Limited; Baxalta Incorporated, Baxalta US Inc., and Baxalta GmbH; Genentech, Inc.; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.